Balaxi Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Balaxi Pharmaceuticals has a total shareholder equity of ₹2.2B and total debt of ₹303.3M, which brings its debt-to-equity ratio to 14.1%. Its total assets and total liabilities are ₹2.9B and ₹721.0M respectively. Balaxi Pharmaceuticals's EBIT is ₹457.0M making its interest coverage ratio 24.8. It has cash and short-term investments of ₹608.7M.
Key information
14.1%
Debt to equity ratio
₹303.30m
Debt
| Interest coverage ratio | 24.8x |
| Cash | ₹608.67m |
| Equity | ₹2.16b |
| Total liabilities | ₹720.97m |
| Total assets | ₹2.88b |
Recent financial health updates
Is Balaxi Pharmaceuticals (NSE:BALAXI) A Risky Investment?
Jan 21
These 4 Measures Indicate That Balaxi Pharmaceuticals (NSE:BALAXI) Is Using Debt Reasonably Well
Jul 30Balaxi Pharmaceuticals (NSE:BALAXI) Has A Pretty Healthy Balance Sheet
Feb 09Is Balaxi Pharmaceuticals (NSE:BALAXI) A Risky Investment?
Aug 08Recent updates
Is Balaxi Pharmaceuticals (NSE:BALAXI) A Risky Investment?
Jan 21Balaxi Pharmaceuticals (NSE:BALAXI) Strong Profits May Be Masking Some Underlying Issues
Nov 13These 4 Measures Indicate That Balaxi Pharmaceuticals (NSE:BALAXI) Is Using Debt Reasonably Well
Jul 30Balaxi Pharmaceuticals Limited's (NSE:BALAXI) Share Price Could Signal Some Risk
May 29Market Might Still Lack Some Conviction On Balaxi Pharmaceuticals Limited (NSE:BALAXI) Even After 38% Share Price Boost
Feb 10Balaxi Pharmaceuticals (NSE:BALAXI) Has A Pretty Healthy Balance Sheet
Feb 09Is Balaxi Pharmaceuticals (NSE:BALAXI) A Risky Investment?
Aug 08The Trend Of High Returns At Balaxi Pharmaceuticals (NSE:BALAXI) Has Us Very Interested
May 20A Look At The Intrinsic Value Of Balaxi Pharmaceuticals Limited (NSE:BALAXI)
Feb 03Calculating The Intrinsic Value Of Balaxi Pharmaceuticals Limited (NSE:BALAXI)
Sep 06Balaxi Pharmaceuticals (NSE:BALAXI) Knows How To Allocate Capital Effectively
Jun 03Is Weakness In Balaxi Pharmaceuticals Limited (NSE:BALAXI) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Mar 12Is Balaxi Pharmaceuticals Limited's(NSE:BALAXI) Recent Stock Performance Tethered To Its Strong Fundamentals?
Nov 27
Financial Position Analysis
Short Term Liabilities: BALAXI's short term assets (₹2.4B) exceed its short term liabilities (₹693.2M).
Long Term Liabilities: BALAXI's short term assets (₹2.4B) exceed its long term liabilities (₹27.7M).
Debt to Equity History and Analysis
Debt Level: BALAXI has more cash than its total debt.
Reducing Debt: BALAXI's debt to equity ratio has increased from 0% to 14.1% over the past 5 years.
Debt Coverage: BALAXI's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: BALAXI's interest payments on its debt are well covered by EBIT (24.8x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 04:44 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Balaxi Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.